Selmaj K, Cree B, Barnett M, Thompson A, Hartung H
J Neurol. 2023; 271(1):105-115.
PMID: 37851189
PMC: 10769939.
DOI: 10.1007/s00415-023-11969-8.
Sattarnezhad N, Healy B, Baharnoori M, Diaz-Cruz C, Stankiewicz J, Weiner H
BMC Neurol. 2022; 22(1):252.
PMID: 35820822
PMC: 9277810.
DOI: 10.1186/s12883-022-02761-8.
Vermersch P, Shanahan J, Langdon D, Yeandle D, Alexandri N, Schippling S
Neurol Ther. 2019; 9(1):1-10.
PMID: 31748873
PMC: 7229099.
DOI: 10.1007/s40120-019-00170-7.
Col N, Alvarez E, Springmann V, Ionete C, Morales I, Solomon A
MDM Policy Pract. 2019; 4(2):2381468319879134.
PMID: 31667351
PMC: 6798166.
DOI: 10.1177/2381468319879134.
Giannetti P, Niccolini F, Nicholas R
Degener Neurol Neuromuscul Dis. 2019; 2:119-132.
PMID: 30890883
PMC: 6065565.
DOI: 10.2147/DNND.S35790.
Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis.
Nwankwo E, Allington D, Rivey M
Degener Neurol Neuromuscul Dis. 2019; 2:15-28.
PMID: 30890875
PMC: 6065561.
DOI: 10.2147/DNND.S29022.
Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study.
Cohan S, Smoot K, Kresa-Reahl K, Garland R, Yeh W, Wu N
Adv Ther. 2018; 35(11):1894-1904.
PMID: 30341505
PMC: 6223975.
DOI: 10.1007/s12325-018-0799-5.
Advances in the treatment of relapsing-remitting multiple sclerosis: the role of pegylated interferon β-1a.
Furber K, Van Agten M, Evans C, Haddadi A, Doucette J, Nazarali A
Degener Neurol Neuromuscul Dis. 2018; 7:47-60.
PMID: 30050377
PMC: 6053102.
DOI: 10.2147/DNND.S71986.
Treatment satisfaction and quality of life in patients treated with fingolimod.
Mekies C, Heinzlef O, Jenny B, Ramelli A, Clavelou P
Patient Prefer Adherence. 2018; 12:899-907.
PMID: 29872275
PMC: 5973401.
DOI: 10.2147/PPA.S144021.
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C
J Neurol. 2018; 265(5):1174-1183.
PMID: 29549468
DOI: 10.1007/s00415-018-8831-x.
Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.
Becker V, Heeschen V, Schuh K, Schieb H, Ziemssen T
Ther Adv Neurol Disord. 2018; 11:1756285617748845.
PMID: 29399052
PMC: 5788086.
DOI: 10.1177/1756285617748845.
Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
Fernandez O, Duran E, Ayuso T, Hernandez L, Bonaventura I, Forner M
PLoS One. 2017; 12(10):e0185766.
PMID: 29049356
PMC: 5648132.
DOI: 10.1371/journal.pone.0185766.
Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis.
Hincapie A, Penm J, Burns C
J Manag Care Spec Pharm. 2017; 23(8):822-830.
PMID: 28737987
PMC: 10398239.
DOI: 10.18553/jmcp.2017.23.8.822.
Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.
Melesse D, Marrie R, Blanchard J, Yu B, Evans C
Patient Prefer Adherence. 2017; 11:1093-1101.
PMID: 28721023
PMC: 5499788.
DOI: 10.2147/PPA.S138263.
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.
Freedman M, Wolinsky J, Truffinet P, Comi G, Kappos L, Miller A
Mult Scler J Exp Transl Clin. 2017; 1:2055217315618687.
PMID: 28607708
PMC: 5433345.
DOI: 10.1177/2055217315618687.
Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE.
Donze C, Malapel L, Kwiatkowski A, Lenne B, Louchard P, Neuville V
Mult Scler J Exp Transl Clin. 2017; 1:2055217315600720.
PMID: 28607703
PMC: 5433406.
DOI: 10.1177/2055217315600720.
Evaluation of the Adherence to Immunmodulatory Treatment in Patients with Multiple Sclerosis.
Koskderelioglu A, Gedizlioglu M, Ortan P, Ocek O
Noro Psikiyatr Ars. 2017; 52(4):376-379.
PMID: 28360743
PMC: 5353111.
DOI: 10.5152/npa.2015.8825.
Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.
Jernas L, Wencel J, Wiak A, Bieniek M, Bartosik-Psujek H
PLoS One. 2016; 11(10):e0157950.
PMID: 27695075
PMC: 5047441.
DOI: 10.1371/journal.pone.0157950.
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.
Cohan S
Biologics. 2016; 10:119-38.
PMID: 27672308
PMC: 5026217.
DOI: 10.2147/BTT.S89218.
Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.
Fernandez O, Arroyo R, Martinez-Yelamos S, Marco M, Merino J, Munoz D
PLoS One. 2016; 11(8):e0160313.
PMID: 27526201
PMC: 4985132.
DOI: 10.1371/journal.pone.0160313.
